← back to search

Sare Verstockt

KU Leuven · BE
Area of research
Genetics · Epidemiology
Research interest
Research focused on Inflammatory bowel disease and Vedolizumab, with related work in Ulcerative colitis, Oncostatin M, Infliximab. Notable publications include 'Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease', 'Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease', and 'Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease'.
h-index
citations
994
works
13
NIH funding
primary concept
email

Recent publications

P0032 Preliminary single-nuclei RNA sequencing of creeping fat in Crohn’s disease uncovers adipocyte and immune cell remodelling
Journal of Crohn s and Colitis 2026cited by 0position: lastdoi
Intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates fibrostenosis in Crohn’s disease
Journal of Clinical Investigation 2024cited by 40position: middledoi
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
Inflammatory Bowel Diseases 2021cited by 78position: firstdoi
Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon
Journal of Crohn s and Colitis 2020cited by 54position: middledoi
Extracellular Vesicles in Inflammatory Bowel Disease: Small Particles, Big Players
Journal of Crohn s and Colitis 2020cited by 45position: middledoi
Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis
Inflammatory Bowel Diseases 2020cited by 45position: middledoi
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
EBioMedicine 2019cited by 169position: middledoi
Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases
Clinical Gastroenterology and Hepatology 2019cited by 76position: middledoi
Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
Alimentary Pharmacology & Therapeutics 2019cited by 69position: middledoi
Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)
Expert Opinion on Therapeutic Targets 2019cited by 55position: firstdoi
Gene and Mirna Regulatory Networks During Different Stages of Crohn’s Disease
Journal of Crohn s and Colitis 2019cited by 48position: firstdoi
TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn’s disease patients?
Gut 2018cited by 53position: middledoi
Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease
Inflammatory Bowel Diseases 2017cited by 262position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Séverine Vermeire · Europe Hospitals10 papers (2017–2021)Marc Ferrante · Universitair Ziekenhuis Leuven9 papers (2017–2021)Bram Verstockt · Imelda Hospital9 papers (2018–2021)Isabelle Cleynen · KU Leuven6 papers (2017–2021)Gert Van Assche · KU Leuven6 papers (2017–2019)Gert De Hertogh · Spaarne Gasthuis3 papers (2019–2021)Maaike Vancamelbeke · KU Leuven3 papers (2017–2021)Paul Rutgeerts · KU Leuven2 papers (2017–2019)Ingrid Arijs · Hasselt University2 papers (2017–2019)Kathleen Machiels · KU Leuven2 papers (2019–2021)Jonas Dehairs · KU Leuven2 papers (2019–2019)Kaline Arnauts · KU Leuven2 papers (2019–2020)Christine Breynaert · KU Leuven2 papers (2019–2019)Gianluca Matteoli · KU Leuven2 papers (2020–2026)Helene Blevi · KU Leuven2 papers (2018–2019)Frans Schuit · KU Leuven2 papers (2017–2019)João Sabino · Madigan Army Medical Center2 papers (2020–2020)Leentje Van Lommel · KU Leuven1 papers (2019–2019) · 1 papers (2026–2026) · 1 papers (2026–2026)